Senti Biosciences has appointed Gary Lee to serve as chief scientific officer. Lee comes to the South San Francisco, CA, biotech from Sangamo Therapeutics (NASDAQ: [[ticker:SGMO]]), where he was vice president of cell therapy. Senti emerged in February with $53 million in Series A financing to support its cell therapy research.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
